Perspectives on lecanemab, the monoclonal antibody treatment for Alzheimer’s disease
Posted at2022-10-19
Drugmakers Biogen Inc. (BIIB) and Eisai Co., Ltd. (ESALY) announced that
lecanemab, a monoclonal antibody treatment for Alzheimer’s disease,
slows cognitive decline. Tegus was the most efficient way for investors
to quickly understand Biogen and Eisai’s perspectives, their pipeline,
and where the treatment fits in the landscape.